Date: 2011-10-06
Type of information: R&D agreement
Compound: technology platform rePAX™
Company: Redbiotech (Switzerland) Merck&co (USA)
Therapeutic area: undisclosed
Type agreement: R&D
Action mechanism: With the rePAXTM technology, Redbiotec can copy viruses (or parts of them) as nature-like virus-like particles (VLPs), which are functional but non-replicating and therefore non-hazardous. Through this, all viral diseases are addressable.
Disease: undisclosed
Details: Redbiotec has entered into collaboration with Merck Sharp & Dohme Corp. (NJ, USA), in which it will apply its proprietary technology platform rePAX™ to an undisclosed discovery area.
Financial terms:
Latest news:
